In patients with sepsis, thymosin α1 based therapy was associated with lower all-cause mortality in a meta-analysis of 12 trials (pooled RR 0.68, 95% CI 0.59-0.78).
In plain wordsIn people with sepsis, thymosin α1 based therapy was linked to fewer deaths in pooled trials of mixed quality.
- Peptide
- Thymosin alpha-1
- Outcome
- DecreaseAll-cause mortality
- Study
n = 1,480
- Outcome group
- Mortality · Infection
- Studied dose
- Dose not stated
Measurements
- RR
- 0.68
- all-cause mortality
Source sentences
Tα1 based immunomodulatory therapy had a significant trend toward lower all-cause mortality among patients with sepsis (pooled risk ratio 0.68, 95%CI 0.59-0.78, p<0.00001, 12 trials, n=1480).
1 context sentence(design, population, supporting numbers)
Twelve controlled trials were evaluated in all.